Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation

BACKGROUND: Human cytomegalovirus (HCMV) causes a ubiquitous infection which can pose a significant threat for immunocompromised individuals, such as those undergoing solid organ transplant (SOT). Arguably, the most successful vaccine studied to date is the recombinant glycoprotein-B (gB) with MF59...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraniak, Ilona, Gomes, Ariane C., Sodi, Isabella, Langstone, Toby, Rothwell, Emily, Atkinson, Claire, Pichon, Sylvie, Piras-Douce, Fabienne, Griffiths, Paul D., Reeves, Matthew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921368/
https://www.ncbi.nlm.nih.gov/pubmed/31735553
http://dx.doi.org/10.1016/j.ebiom.2019.11.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921368/
https://www.ncbi.nlm.nih.gov/pubmed/31735553
http://dx.doi.org/10.1016/j.ebiom.2019.11.005

Ejemplares similares